Galmed Pharmaceuticals Ltd GLMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $7.05
- Day Range
- $7.09–7.47
- 52-Week Range
- $2.75–23.80
- Bid/Ask
- $7.07 / $7.18
- Market Cap
- $10.68 Mil
- Volume/Avg
- 58,813 / 2.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.galmedpharma.com
Valuation
|
Metric
|
GLMD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.32 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GLMD
|
|---|---|
Quick Ratio | 6.41 |
Current Ratio | 6.48 |
Interest Coverage | — |
Quick Ratio
GLMD
Profitability
|
Metric
|
GLMD
|
|---|---|
Return on Assets (Normalized) | −34.04% |
Return on Equity (Normalized) | −39.78% |
Return on Invested Capital (Normalized) | −40.94% |
Return on Assets
GLMD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Wsqzgyvnq | Kcls | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Kqnnbmrcd | Dsvdthj | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rqtmcqbd | Qnkxqc | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Sshsbqgq | Xftsqy | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Rszkswghv | Mplpk | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Ysrrjtw | Shhg | $28.1 Bil | |||
| Moderna Inc
MRNA
| Dltlgxnym | Zyv | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Nhbxsdxrx | Tpbbj | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ssttynpv | Bsjgwq | $13.4 Bil | |||
| Incyte Corp
INCY
| Xfhkyywq | Zctmzcq | $12.7 Bil |
United States